Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Reabsorption" patented technology

In renal physiology, reabsorption or tubular reabsorption is the process by which the nephron removes water and solutes from the tubular fluid (pre-urine) and returns them to the circulating blood. It is called reabsorption (and not absorption) both because these substances have already been absorbed once (particularly in the intestines) and because the body is reclaiming them from a postglomerular fluid stream that is well on its way to becoming urine (that is, they will soon be lost to the urine unless they are reclaimed). Substances are reabsorbed from the tubule into the peritubular capillaries. This happens as a result of sodium transport from the lumen into the blood by the Na⁺/K⁺ATPase in the basolateral membrane of the epithelial cells. Thus, the glomerular filtrate becomes more concentrated, which is one of the steps in forming urine. Reabsorption allows many useful solutes (primarily glucose and amino acids), salts and water that have passed through Bowman's capsule, to return to the circulation. These solutes are reabsorbed isotonically, in that the osmotic potential of the fluid leaving the proximal convoluted tubule is the same as that of the initial glomerular filtrate. However, glucose, amino acids, inorganic phosphate, and some other solutes are reabsorbed via secondary active transport through cotransport channels driven by the sodium gradient.

Lactococcus lactis SWU-HX39 for relieving hyperuricemia

ActiveCN120060047BInflammatory factorsPediococcus sp.
The present application discloses a lactic acid pediococcus SWU-HX39 with the function of reducing uric acid, and the classification name is lactic acid pediococcus (Pediococcus acidilactici) Pediococcus acidilactici ), which is preserved in the China General Microbiological Culture Collection Center, with the preservation number of CGMCC No.33055, the preservation date of December 13, 2024, and the preservation address of No.3, Xili, Beichen West Road, Chaoyang District, Beijing. The lactic acid pediococcus SWU-HX39 can relieve the kidney damage caused by high uric acid, reduce the synthesis of uric acid, lower the concentration of uric acid in blood, improve the excretion of uric acid in the body, reduce the reabsorption of uric acid in the body, and achieve the effect of reducing uric acid. In addition, SWU-HX39 can reduce the expression of LPS and the expression of inflammatory factors IL-1beta, IL-6 and TNF alpha. That is, it has the functions of anti-inflammation and relieving liver inflammation, and can also increase the content of SCFAs in the body of patients with high uric acid, especially propionic acid, so as to reduce the uric acid level and improve the abnormal uric acid content.
Owner:SOUTHWEST UNIV

Gallus gallus domesticus beta-lactoglobulin reabsorption-mediated gambogic acid renal delivery system, synthetic method and application thereof

This invention belongs to the field of biomedicine and nanomedicine delivery technology, and relates to a precise renal-targeted delivery system for gambogeylic acid mediated by the β-lactoglobulin reabsorption mechanism, its synthesis method, and applications. The system comprises β-lactoglobulin-PEG-gambogeylic acid nanoparticles, containing β-lactoglobulin as a targeting carrier and gambogeylic acid as the active ingredient, covalently linked by a polyethylene glycol chain. This invention utilizes the suitable molecular size of β-lactoglobulin and its ability to be recognized and reabsorbed by the megalin / cubilin receptor system of renal tubular epithelial cells to construct a nanodelivery system that mimics the physiological process of endogenous protein "filtration-reabsorption." Experiments have shown that this system significantly improves the water solubility and biocompatibility of gambogeylic acid, enabling selective accumulation in the kidneys and efficient capture by renal tubular epithelial cells in vivo. It exhibits superior therapeutic effects in a mouse model of cisplatin- and glycerol-induced acute kidney injury, significantly outperforming the positive control drug NAC.
Owner:JIANGSU UNIV OF SCI & TECH